Aim: HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population. Materials & methods: Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test. Results: A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes. Conclusion: A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated.
Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men / Giuliani, Massimo; Latini, Alessandra; Colafigli, Manuela; Benevolo, Maria; Rollo, Francesca; Zaccarelli, Mauro; Giuliani, Eugenia; Moretto, Domenico; Giglio, Amalia; Rezza, Giovanni; Cristaudo, Antonio; Donà, Maria G.. - In: FUTURE MICROBIOLOGY. - ISSN 1746-0913. - 13:13(2018), pp. 1463-1472. [10.2217/fmb-2018-0149]
Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men
ROLLO, FRANCESCA;Giuliani, Eugenia;
2018
Abstract
Aim: HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population. Materials & methods: Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test. Results: A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes. Conclusion: A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated.| File | Dimensione | Formato | |
|---|---|---|---|
|
Giuliani_Vaccine-preventable_2018.pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.45 MB
Formato
Adobe PDF
|
1.45 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
